Trial Profile

HI FPV Study: Using Observational Cohorts to Monitor Safety of Fosamprenavir in Patients With Mild/Moderate Hepatic Impairment.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosamprenavir (Primary) ; Antiretrovirals; Lopinavir/ritonavir; Ritonavir
Indications HIV infections
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

01 May 2016 Retrospective multicohort analysis (n=1096) assessing the safety and tolerability of fosamprenavir/ritonavir in HIV-infected subjects with viral hepatitis co-infection were published in the HIV Clinical Trials.
27 Jun 2011 Planned end date changed from 1 Jan 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
30 Jan 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com